

## Zespół ds. leczenia chłoniaków

Publikacje w roku 2018	IF	MNIŚW
<a href="#">Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.</a> Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Lancet. 2018 Dec 3. pii: S0140-6736(18)32984-2. doi: 10.1016/S0140-6736(18)32984-2. [Epub ahead of print]	79,258	50,0
<a href="#">Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.</a> Hohloch K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, Cacchione R, <b>Jurczak W</b> , Bischof Delaloye A, Trümper L, Scholz CW. Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15712. [Epub ahead of print]	5,128	40,0
<a href="#">Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial.</a> Ogura M, Sancho JM, Cho SG, Nakazawa H, Suzumiya J, Tumyan G, Kim JS, Lennard A, Mariz J, Ilyin N, <b>Jurczak W</b> , Lopez Martinez A, Samoiloova O, Zhavrid E, Yañez Ruiz E, Trneny M, Popplewell L, Coiffier B, Buske C, Kim WS, Lee SJ, Lee SY, Bae YJ, Kwak LW. Lancet Haematol. 2018 Nov;5(11):e543-e553. doi: 10.1016/S2352-3026(18)30157-1.	10,698	35,0
<a href="#">Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.</a> Długosz-Danecka M, Gruszka AM, Szmit S, Olszanecka A, Ogórka T, Sobociński M, Jaroszyński A, Krawczyk K, Skotnicki AB, <b>Jurczak W</b> . Chemotherapy. 2018;63(4):238-245. doi: 10.1159/000492942. Epub 2018 Oct 29.	2,000	15,0
<a href="#">The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions.</a> <b>Jurczak W</b> , Długosz-Danecka M, Rivas Navarro F. Future Oncol. 2018 Oct 3. doi: 10.2217/fo-2018-0388. [Epub ahead of print]	2,369	25,0
<a href="#">Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.</a> <b>Jurczak W</b> , Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. Br J Haematol. 2018 Nov;183(3):479-490. doi: 10.1111/bjh.15573. Epub 2018 Sep 7.	5,128	40,0
<a href="#">Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.</a> Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, <b>Jurczak</b>	5,128	40,0

<p><b>W</b>, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B. Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.</p>		
<p><a href="#">The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.</a> Zaucha JM, Malkowski B, Chauvie S, Subocz E, Tajer J, Kulikowski W, Fijolek-Warszewska A, Biggi A, Fallanca F, Kobylecka M, Dziuk M, Woszczyk D, Rybka J, Kroll-Balcerzak R, Bergesio F, Romanowicz A, Chamier-Cieminska A, Kurczab P, <b>Giza A</b>, Lesniewski-Kmak K, Zaucha R, Swietlik D, Wróbel T, Knopinska-Posluszny W, Walewski J, Gallamini A. Ann Oncol. 2017 Dec 1;28(12):3051-3057. doi: 10.1093/annonc/mdx524.</p>	13,926	45,0
<p><a href="#">Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.</a> Długosz-Danecka M, <b>Jurczak W</b>, Łątka-Cabała E, Morawska M, Gawroński K, Wiśniewska A, Dudziński M, Wąsik-Szczepanek E, Chmielowska E, Łabędź A, Wdowiak K, Hus I. Pol Arch Intern Med. 2018 Aug 31;128(7-8):421-426. doi: 10.20452/pamw.4294. Epub 2018 Jul 11.</p>	2,658	30,0
<p><a href="#">Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.</a> Wróbel T, Biecek P, Rybka J, Szulgo A, Sorbotten N, Giza A, Tyczyńska A, Nowara E, Badora-Rybicka A, Adamowicz K, Kulikowski W, Kroll-Balcerzak R, Balcerzak A, Spychałowicz W, Kalinka-Warzocho E, Kumiega B, Drozd-Sokołowska J, Subocz E, Sałek A, Machaczka M, Hołojda J, Pogrzeba J, Dobrzyńska O, Chmielowska E, <b>Jurczak W</b>, Knopińska-Postuszny W, Leśniewski-Kmak K, Maciej Zaucha J. Leuk Lymphoma. 2018 Jul 6:1-8. doi: 10.1080/10428194.2018.1482539. [Epub ahead of print]</p>	2,644	25,0
<p><a href="#">[Peripheral blood cell count and inflammation-based markers in chronic rhinosinusitis].</a> Zagólski O, Stręk P, <b>Jurczak W</b>, Gorzedowski P. HNO. 2018 Jun 22. doi: 10.1007/s00106-018-0527-0. [Epub ahead of print] German.</p>	0,893	15,0
<p><a href="#">Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.</a> Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, <b>Jurczak W</b>, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G. J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.</p>	26,303	45,0
<p><a href="#">Use of acalabrutinib in patients with mantle cell lymphoma.</a> Awan FT, <b>Jurczak W</b>. Expert Rev Hematol. 2018 Jun;11(6):495-502. doi: 10.1080/17474086.2018.1473030. Epub 2018 May 14.</p>	1,937	20,0
<p><a href="#">Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.</a> Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, <b>Jurczak W</b>, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi:</p>	26,303	45,0

10.1200/JCO.2017.76.6840. Epub 2018 May 1.		
<a href="#">Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.</a> Rule S, <b>Jurczak W</b> , Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. <i>Leukemia</i> . 2018 Aug;32(8):1799-1803. doi: 10.1038/s41375-018-0023-2. Epub 2018 Feb 2. No abstract available.	10,023	45,0
<a href="#">Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.</a> <b>Jurczak W</b> , Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. <i>Ann Oncol</i> . 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056.	13,926	45,0
<a href="#">Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.</a> Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, <b>Jurczak W</b> . <i>Lancet</i> . 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11.	53,254	50,0
<a href="#">Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.</a> Connors JM, <b>Jurczak W</b> , Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. <i>N Engl J Med</i> . 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: <a href="#">N Engl J Med. 2018 Mar 1;378(9):878.</a>	79,258	50,0
<a href="#">Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.</a> Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, <b>Jurczak W</b> , Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trněný M; SPRINT Trial Investigators. <i>Br J Haematol</i> . 2018 Jan;180(2):224-235. doi: 10.1111/bjh.15025. Epub 2017 Nov 28.	5,128	40,0
	<b>345,962</b>	<b>700</b>